Abstract: The metal complexes of general formula I in which Hal stands for bromine or iodine, and A1 and A2 have different meanings, are suitable as contrast media.

Abstract: Isocyanatosilanes are prepared by themolyzing carbamatosilanes in a fluidized bed reactor containing fluidized solid particles. The process substantially avoids the deposition of solid reaction by products in the reactor.

Abstract: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

Abstract: Terephthalic acid is prepared by reacting a 2,5-furandicarboxylate with ethylene in the presence of a solvent to produce a bicyclic ether; and then dehydrating the bicyclic ether. The process of the present invention effectively produces terephthalic acid, while reducing or eliminating the impurities, color bodies and carbon oxides produced in commercial practice by the liquid-phase oxidation of methyl-substituted benzene feedstocks.

Abstract: Disclosed is an optimized process and apparatus for more efficiently and economically carrying out the liquid-phase oxidation of an oxidizable compound. Such liquid-phase oxidation is carried out in a bubble column reactor that provides for a highly efficient reaction at relatively low temperatures. When the oxidized compound is para-xylene and the product from the oxidation reaction is crude terephthalic acid (CTA), such CTA product can be purified and separated by more economical techniques than could be employed if the CTA were formed by a conventional high-temperature oxidation process.

Abstract: One object of the present invention is to provide a drug that is effective in treatments for and prevention of psychiatric disorders and in treatments for and prevention of neurological diseases, inhibiting a Group II metabotropic glutamate receptor. The object is solved by a 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative represented by formula [I]: (wherein R1 and R2 are the same or different, and each represents a hydrogen atom, C1-10alkyl group, etc; X represents a hydrogen atom or a fluorine atom; and Y represents an amino group, —SR3, —S(O)nR7, —SCHR3R4, —S(O)nCHR3R4, —NHCHR3R4, —N(CHR3R4)(CHR5R6), —NHCOR3 or —OCOR7), a pharmaceutically acceptable salt thereof, or a hydrate thereof and so on.

Abstract: A process is disclosed for the production of olefins including ethylene, propylene and butenes from methyl mercaptan. The process comprises a reaction whereby methyl mercaptan decomposes to produce the olefin and hydrogen sulfide. The reaction is carried out at an elevated temperature in the range of 300° C. to 500° C. to achieve pyrolysis. Alternatively, a heterogeneous catalyst may be used.

Abstract: The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor

Abstract: Hydroxy aromatic acids are produced in high yields and high purity (>95%) from halogenated aromatic acids in a reaction mixture containing a copper source and a ligand that coordinates to copper.

Abstract: A continuous process and system for producing polyether polyols that allows for continuously adding an unreacted oxide to a loop reactor while adding at least one thermally deactivating catalyst capable of thermally deactivating prior to decomposition of polyether polyol which can allow for greater concentrations of unreacted oxides and/or a rate of reaction in the loop reactor is at a rate at least two times faster than a rate of reaction in a loop reactor containing less than 14 weight percent unreacted oxide. In a preferred embodiment, the catalyst is a double metal cyanide catalyst and a plug flow reactor is formed in series with the loop reactor wherein neither reactor contains a vapor space.

Abstract: Compounds of formula (I): wherein R1 represents optionally substituted C4-12 alkyl, optionally substituted C2-6alkylaryl, or optionally substituted 5- or 6-membered aryl or heteroaryl; Z represents a bond, CH2, O, S, SO, SO2, NR4, OCR4R5, CR4R5O, or Z, R1 and Q together form an optionally substituted fused tricyclic group; Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring; X represents COR3 or N(OR8)COR9; R2 represents SO2R10 or SO2NR10R11; R3 represents OR6, NR6R7 or NR6OH; R4 and R5 each independently represents H, C1-6 alkyl or C1-4 alkylaryl; R6 and R7 each independently represents H, C1-6 alkyl, or C1-6 alkyl substituted with one or more heteroaryl groups, or R6 and R7 together with the nitrogen atom to which they are attached form a 5- or 6-membered ring which may optionally include 1 or more further heteroatoms selected from O, S and N; R8 and R9 each independently represents H or C1-6 alkyl; R10 and R11 each independently represents H or C1-6 alkyl; and and physiolo

Abstract: A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)-propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the presence of an optically active catalyst to reduce 1-indanones. The chiral product, either (S)- or (R)-indanols undergo nucleophilic substitution to produce the named product. In an additional aspect, the invention relates to novel intermediates and compounds, namely, substituted indanones, substituted (S)-indanols and substituted (R)-indanols.

Abstract: A method for producing MMA-d8 which includes a step of exchanging D in hydroxyl group of methanol-d4 represented by the formula: CD3OD with H to prepare the methanol-d3 represented by the formula CD3OH and simultaneously recovering a deuterium-containing compound, and a step of reacting methanol-d3 with sulfuric acid salt of methacrylic acid amide represented by the formula CD2=(CD3)CO(NH2.H2SO4) to prepare MMA-d8 represented by the formula: CD2=(CD3)COOCD3.

Abstract: A process for the synthesis of (per)fluorinated mono-functional carbonyl compounds having the following formula (I): F-A-RF—B—C(O)X1??(I) wherein: X1=F, CF3; A, B equal to or different from each other, are independently (per)fluoroalkylene or (per)fluorooxyalkylene groups; RF is —ORf1O— wherein Rf1=perfluoroalkylene or —ORf2, wherein Rf2 is a perfluorooxyalkylene chain; said process comprising the following steps: A) obtainment of the formula (II) mono-hypofluorite: FO—CFX2-A-RF—B—C(O)X1??(II) by partial fluorination with elemental fluorine of the carbonyl groups of the formula (III) compound: X2(O)C-A-RF—B—C(O)X1??(III) in the presence of a formula MeFy catalyst, Me being an alkaline or alkaline-earth metal or Ag, y=1 or 2; B) thermal decomposition of the compound (II) to give the compounds according to the following scheme: FO—CFX2-A-RF—B—C(O)X1 (II) - - - ?F-A-RF—B—C(O)X1 (I)+(O)CFX2.

Abstract: Compounds having a formula: or a pharmaceutically acceptable salt or prodrug thereof, are provided, and are useful for the treatment of metabolic disorders.

Abstract: A description is given of a process for preparing aldehydes, carboxylic acids and/or carboxylic anhydrides, in particular phthalic anhydride, in which a gaseous stream comprising an aromatic hydrocarbon and molecular oxygen is passed at elevated temperature over a bed of a first catalyst and a bed which is made up of a second catalyst having a higher activity than the first catalyst and is located downstream of the first catalyst in the flow direction of the gaseous stream, wherein the catalytically active composition of the first catalyst comprises at least vanadium oxide, titanium dioxide and antimony oxide and the ratio of vanadium, calculated as V2O5, to antimony, calculated as Sb2O3, in the first catalyst is from 3.5:1 to 5:1. The source of antimony oxide used for the first catalyst is preferably particulate antimony trioxide having a mean particle size of from 0.5 to 5 ?m. The process allows the desired oxidation products to be obtained in high yield over longer periods of time.

Abstract: Disclosed is a process for the synthesis of 1,3,3,3-tetrafluoropropene which comprises, in one embodiment, reacting a compound of CF3X1 with a compound of CX2H?CHX3, wherein X1, X2, and X3 are each independently selected from the group consisting of fluorine, chlorine, bromine and iodine, to produce a reaction product comprising a compound of CF3CH?CHX3, wherein X3 is as described above; and when X3 is not fluorine, fluorinating the compound to produce 1,3,3,3-tetrafluoropropene. The process in another embodiment comprises preparing tetrafluoropropene comprising thermally cracking one or more compounds capable of producing a reaction mixture which preferably comprises diflurocarbene radicals and vinylidene fluoride, and converting said reaction mixture into—tetrafluoropropene (1,3,3,3-tetrafluoropropene).

Abstract: Process for the preparation of an alkynol with formula HC?C—CH(OH)—R2(formula 2) wherein R2 represents methyl, halomethyl or ethyl, wherein the corresponding silyl-protected alkynol ester with formula 1 wherein R1 represents H, or an optionally substituted alkyl, an optionally substituted alkenyl or an optionally substituted (hetero)aryl group, R2 is as defined above and A3Si represents a trisubstituted silyl group wherein each A independently represents an optionally substituted alkyl or an optionally substituted (hetero)aryl group, in the presence of water and at least an equivalent amount of amine functionalities is converted into the alkynol with formula 2. Preferably, the amount of water is between 0.5 and 3 equivalents calculated with respect to the amount of silyl-protected alkynol ester with formula (1).

Abstract: The present invention relates to the development of a hyaluronic acid and hyaluronic acid hybrid nanoparticle systems for the administration of active molecules, peptides, DNA and/or other hydrophilic or hydrophobic molecules, the composition of hyaluronic acid and hyaluronic acid hybrid nanoparticle systems, and the procedure for their development and use. These nanoparticles are made up of hyaluronic acid in salt form, preferentially the sodium salt of the polymers or hybridized with magnetic Fe particles. The nanoparticles are basically from natural polymers, biocompatibles and biodegradables. The nanoparticles allow the controlled release of the active molecules they transport and their orientation towards the target tissues. The present invention teaches a procedure to elaborate particles of hyaluronic acid with a diameter less than 180 nm., that incorporate an active ingredient, independent of its hydrophilic or hydrophobic nature. Procedures to produce the particles are described.

Abstract: The invention relates to a multistage process for continuous and phosgene-free preparation of cycloaliphatic diisocyanates.